Brian Ennis: New President of Implanet America

Brian T. Ennis is the new President of Implanet America, a company specializing in vertebral and knee-surgery implants.

Ennis said in the February 12, 2016 news release, “It is a true privilege to join the Implanet team. I welcome the opportunity to lead the division through an aggressive expansion in the U.S. market. I am quite confident that there is tremendous upside with respect to applying sub-laminar band technology to both the Deformity and Degenerative Spine market Segments.”

Ludovic Lastennet, CEO of Implanet, added, “We are delighted to be able to welcome Brian to lead Implanet’s U.S. management team. His experience, strategic vision and managerial skills will enable him to successfully execute Implanet’s ambitious growth plan in the United States. During his career, he has proven his ability to meet every new challenge by obtaining outstanding results, whatever the issue. The successes he has recorded throughout his career make Brian a natural leader for our American subsidiary, which now has a solid sales team and more than 25 partner agencies covering 60% of the country. I am confident that Brian will be instrumental in helping us reach incremental major milestones in our development.”

As indicated in the news release, “Ennis began his career with C.R. Bard in Sales and was rapidly promoted into a marketing management role. After a long tenure at Stryker Corporation in a variety of Marketing and General Management roles in the United States and Europe, he served as the President of International for Wright Medical Group, which specializes in biotechnology and orthopedic devices. Brian was then appointed as the President of Empi, the premier provider of electrotherapeutic medical solutions and pain management successfully leading the company through an integration with a major competitor. Subsequently, Brian was appointed as the President and CEO at Etex Corporation, marshaling the transformation of this start-up specializing in the Research & Development of biomaterials into a profitable and viable high-growth company. Brian has served Implanet as an Independent Board Director and Special Advisor for the past 2 years.”

Ennis told OTW, “Our initial steps will focus on aggressively accelerating our sales momentum by rapidly expanding our sales force to maximize coverage, recruiting additional key opinion leaders to facilitate a surgeon driven product development initiative, and documenting the clinical efficacy of JAZZ technology in both the degenerative and deformity spine market segments.”